Among the top ranked oncogenes, ABL1_BCR ranked first with connections to 28 drugs, followed by BCR_ABL1 and KRAS with 20 and 12 drugs (Figure 2D), implying that the highly drug-connected genes that are not currently identified as cancer genes could actually be causally implicated in cancer therapy, such as KCTD1_PCAT18 fusion, TNFRSF9, LTB, and NFATC4, which showed connections to over 18 drugs and ranked as the top five genes (Supplementary Figure S2). This evidence concerns the gene ABL1 and cancer.